Alle News zum Sektor Gesundheit

 

HeraMED Phase 1 Lee Health digital obstetrics pilot validates HeraCARE; 44 patients, 92% adopt digital path; Phase 2 decision soon....

With more than 600k average monthly users on the HotCopper forums, each…...

Evotec hat nach vorläufigen Zahlen für das erste Halbjahr 2026 den Ausblick für das Gesamtjahr deutlich nach unten korrigiert. Sowohl die Umsatz- als auch die Ergebnisprognose wurden erheblich reduziert. Wie das Unternehmen per Ad-hoc-Mitteilung bekannt gab, erwartet Evotec für das erste Halbjahr 2026 einen Konzernumsatz von rund 300,1 Mio. EUR sowie ein bereinigtes EBITDA von […]...

Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full-year revenue guidance, among others....

STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection......

PHARMARON (03759.HK) issued a positive profit alert, expecting interim revenue for the period ended end-Jun this year to reach approximately RMB7.472 billion to RMB7.665 billion, up 16% to 19% YoY. Net profit is expected to be approximately RMB729 million to RMB772 million, up 4% to 10% YoY. Net profit after deducting non-recurr......

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, August 24, 2026....

The biotech is advancing a potential treatment for a common autoimmune disease....

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial....

Die Deutsche Krankenhausgesellschaft glaubt an eine neue Insolvenzwelle. Jede dritte Klinik könnte das von der schwarz-roten Koalition beschlossene Krankenkassen-Sparpaket nicht überleben....

This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities....

Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close....

The latest trading day saw Canopy Growth Corporation (CGC) settling at $0.96, representing a -1.15% change from its previous close....

Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close....

Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day....

Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close....

NEW YORK, July 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline.......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day....